For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-transdermal-patch-market-and-clinical-pipeline-outlook-2022.php
Table of Contents
-
Introduction to Transdermal Patch
-
Classification of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch
-
Why There Exist Need for Transdermal Patches?
-
Mechanism of Transdermal Patch Drug Delivery
4.1 Properties of Transdermal Therapeutics
4.2 Components of Transdermal Patch
4.3 Mechanism of Motion Sickness, Nicotine and Female Contraceptive Transdermal Patch
-
Transdermal Patch v/s Traditional Drug Delivery Methods
-
Global Transdermal Patch Market Outlook
6.1 Global Market Scenario
6.2 Regional Trends
-
Global Transdermal Patch Clinical Pipeline Overview
7.1 By Phase
7.2 By Region/Country
7.3 By Drug Class/Molecule
7.4 By Company
7.5 By Orphan and Fast Track Status
7.6 By Mode of Action
-
Global Transdermal Patch Market Dynamics
8.1 Favorable Market Parameters
8.2 Commercialization Challenges
-
Global Transdermal Patch Market Future Prospects
-
Global Transdermal Patch Clinical Insight
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered
-
Marketed Transdermal Patch Clinical Insight by Company, Indication and Phase
-
Competitive Landscape
12.1 3M Pharmaceuticals
12.2 Acrux
12.3 Agile Therapeutics
12.4 Allergan
12.5 ANI Pharmaceuticals
12.6 Antares Pharma
12.7 Bayer HealthCare Pharmaceuticals
12.8 Corium International
12.9 Chase Pharmaceuticals
12.10 DURECT Corporation
12.11 Endo Pharmaceuticals
12.12 Fempharm
12.13 Hisamitsu Pharmaceutical
12.14 Immune Pharmaceuticals
12.15 Imprimis Pharmaceuticals
12.16 Ipsen Bioscience
12.17 Johnson and Johnson
12.18 LaSalle Laboratories
12.19 Lavipharm-increase
12.20 MINRAD International
12.21 NeurogesX
12.22 Noven Pharmaceuticals
12.23 NuPathe
12.24 Nuvo Research
12.25 Novartis
12.26 Pain Therapeutics
12.27 ProStrakan
12.28 Purdue Pharma
12.29 Sanofi
12.30 Scilex Pharmaceuticals
12.31 Senju Pharmaceutical
12.32 Somerset Pharmaceuticals
12.33 Teikoku Seiyaku
12.34 Therapeutic Discovery Corporation
12.35 Transdermal Delivery Solutions Corp
12.36 UCB-full form
12.37 Xel Pharmaceuticals
12.38 Zosano Pharma
Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 4-1: Properties of Transdermal Therapeutics
Figure 4-2: Components of Transdermal Patch
Figure 4-3: Types of Permeation Enhancers
Figure 4-4: Schematic Representation of Iontophoresis
Figure 4-5: Mechanism of Scopolamine Transdermal Patch
Figure 4-6: Mechanism of Nicotine Transdermal Patch
Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 5-1: Issues with Traditional Drug Delivery Methods
Figure 5-2: Advantages of Transdermal Patch
Figure 5-3: Consistent Drug Supply by Transdermal Patch
Figure 6-1: Global andndash; Transdermal Patch Market Opportunity (US$ Billion), 2016-2022
Figure 7-1: Global andndash; Transdermal Patch Pipeline by Phase (%), 2017 till 2022
Figure 7-2: Global andndash; Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
Figure 7-3: Global andndash; Transdermal Patch Pipeline by Phase (%), 2017 till 2022
Figure 7-4: Global andndash; Transdermal Patch Pipeline by Phase (Number), 2017 till 2022
Figure 7-5: Global – Transdermal Patch Pipeline by Region (%), 2017 till 2022
Figure 7-6: Global – Transdermal Patch Pipeline by Country (%), 2017 till 2022
Figure 7-7: Global – Transdermal Patch Pipeline by Drug Class/Molecule (%), 2017 till 2022
Figure 7-8: Global – Transdermal Patch Pipeline by Company (%), 2017 till 2022
Figure 7-9: Global – Transdermal Patch Pipeline by Ophan and Fast Track Status (%), 2017 till 2022
Figure 7-10: Global – Transdermal Patch Pipeline by Mode of Action (%), 2017 till 2022
Figure 8-1: Drivers for Transdermal Patch
Figure 8-2: Transdermal Patch Market Commercialization Challenges
Figure 12-1: Acrux Clinical Pipeline
Figure 12-2: Agile Therapeutics Clinical Pipeline
Figure 12-3: Antares Pharma Clinical Pipeline
Figure 12-4: Corium International Clinical Pipeline
Figure 12-5: Durect Corporation Clinical Pipeline
Figure 12-6: Endo Pharmaceuticals Clinical Pipeline
Figure 12-7: Immune Pharmaceuticals Clinical Pipeline
Figure 12-8: Novartis Clinical Pipeline
Figure 12-9: Senju Pharmaceuticals Clinical Pipeline
Figure 12-10: Xel Pharamaceuticals Clinical Pipeline
Figure 12-11: Zosano Pharma Clinical Pipeline
Table 2-1: Differences between Active and Passive Transdermal Patches
Table 4-1: Transdermal Patches for Various Disease Indications
Table 12-1: Pain Therapeutics Clinical Pipeline
